Watchlist Price Alert

Metsera Inc. (MTSR)

NASDAQ: MTSR · Real-Time Price · USD

29.45

0.59 (2.04%)

At close: Jul 03, 2025, 3:20 PM

28.95

-1.70%

After-hours: Jul 03, 2025, 04:44 PM EDT

2.04% (1D)

Bid	28.95
Market Cap	3.09B
Revenue (ttm)	n/a
Net Income (ttm)	-161.21M
EPS (ttm)	-2.54
PE Ratio (ttm)	-11.59
Forward PE	-8.23
Analyst	Buy

Ask	29.62
Volume	589,691
Avg. Volume (20D)	1,070,096
Open	28.76
Previous Close	28.86
Day's Range	28.43 - 30.06
52-Week Range	12.30 - 37.99
Beta	0.40

About MTSR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MTSR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MTSR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

+15.5%

Metsera shares are trading higher after Guggenheim... Unlock content with Pro Subscription

3 weeks ago

+10.55%

Metsera shares are trading higher after the company announced topline data from the Phase 1 clinical trial of MET-233i.

News

1 week ago · zacks.com

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 89.7% in Metsera Inc. (MTSR). While the effectiveness of this highly sought-after metric is questionable, the p...

3 weeks ago · benzinga.com

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Metsera, Inc. MTSR on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability wi...

3 weeks ago · reuters.com

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a mo...